What You Should Know:
- Glooko, a provider of integrated digital health solutions for diabetes management, has announced a significant expansion of its platform's capabilities with the integration of Abbott’s FreeStyle Libre continuous glucose monitoring (CGM) systems in the United States.
- The newly implemented integration allows individuals with diabetes to seamlessly synchronize data from their FreeStyle Libre CGM systems with other vital health metrics, including insulin
Read More
Diabetes Management Platform | Type 1 & 2 Diabetes Patients | News, Analysis, Insights - HIT Consultant
Senseonics and Ascensia Diabetes Care Integrate Eversense® 365 CGM with SweetSpot™ Platform
What You Should Know:
- Senseonics Holdings and Ascensia Diabetes Care today announced the integration of the Eversense® 365 Continuous Glucose Monitoring (CGM) System with the SweetSpot™ diabetes management platform in the U.S.
- The collaboration aims to improve patient care and streamline diabetes management for endocrinology practices and their patients.
Enhance Diabetes Management and Improve Patient Outcomes
The integration allows SweetSpot to seamlessly access and
Read More
Abbott Launches OTC Continuous Glucose Monitor, Lingo
What You Should Know:
- Abbott, a global healthcare company, has announced the U.S. availability of Lingo, a continuous glucose monitoring (CGM) system designed for individuals who want to improve their overall health and wellness.
- Lingo is the first CGM available without a prescription designed for individuals who want to improve their overall health and wellness, regardless of whether they have diabetes.
A Powerful Tool for Health Management
Lingo combines a biosensor
Read More
Physicians Reveals GLP-1s for Weight Loss are Overprescribed and Unsustainable
What You Should Know:
- A large majority of physicians feel GLP-1s are being overprescribed, according to a new survey from Virta Health, a leader in type 2 diabetes reversal.
- The Virta Health survey was conducted in partnership with Beresford Research and included 300 primary care providers, endocrinologists, and obesity specialists across the United States sheds light on the medical community's views on the rapidly growing class of GLP-1 medications, often hailed as
Read More
Abbott Unveils FreeStyle Libre 3 Plus: World’s Smallest CGM Sensor with Future AID Compatibility
What You Should Know:
- At the American Diabetes Association conference, Abbott unveiled a new addition to its FreeStyle Libre portfolio – the FreeStyle Libre 3 Plus sensor.
- The sensor boasts the distinction of being the world's smallest, thinnest, and most discreet continuous glucose monitoring (CGM) sensor available.
Unmatched Design and Performance
The FreeStyle Libre 3 Plus sensor offers a unique combination of user-centric features:
Unmatched Discreetness: The
Read More
POGO Automatic Blood Glucose Monitor Now Covered by Medicare Part B
What You Should Know:
- Intuity Medical, Inc., a medical technology company committed to making it easier to live with diabetes, announced today that its POGO Automatic® Blood Glucose Monitoring (ABGM) system, featuring one-step testing, is now covered by Medicare Part B. This decision expands access to the innovative monitor for the 16.5 million seniors age 65 and up living with
Read More
Report Reveals Digital Diabetes Management Tools Fail to Deliver Benefits, Increase Costs
What You Should Know:
- Digital diabetes management tools are failing to deliver meaningful health benefits to patients, according to a new evaluation by the Peterson Health Technology Institute (PHTI).
- The report casts doubt on the effectiveness of widely used digital diabetes management tools. Despite billions in investment, the study finds these tools offer minimal health benefits and actually increase healthcare spending.
Millions Rely on Tools, But Evidence Shows Little
Read More
Welldoc Awarded FDA 510(k) Clearance for Diabetes Platform
What You Should Know:
Welldoc®, a digital health leader revolutionizing chronic care, today announced the receipt of its 11th 510(k) clearance from the Food and Drug Administration (FDA) for its award-winning diabetes digital health solution, BlueStar®.This clearance immediately follows Welldoc’s 10th 510K clearance announcement earlier this month, solidifying the company’s continued leadership in chronic care innovation.
A Continuous Glucose Monitoring (CGM) Informed Bolus Insulin Dose
Read More
Rimidi Enhances Integration with Dexcom, Adds Glycemic Risk Index to Diabetes Platform
What You Should Know:
Rimidi, a clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives, is announcing enhancements to its diabetes management platform, including the addition of Glycemic Risk Index (GRI) as an emerging tool for patient and population outcomes management.
The inclusion of CGM data and GRI into Rimidi’s platform and clinical workflows is made possible via an enhanced integration with Dexcom, a
Read More
Rimidi and ARKRAY Partner to Bring Glucose Data to the EHR
What You Should Know:
- In an effort to make blood glucose data more actionable for providers and patients alike, Rimidi, a leading clinical management platform announced its integration with the ARKRAY GLUCOCARD® Shine Connex Blood Glucose Monitoring System to Rimidi’s Platform.
- The integration enables providers to manage blood-glucose control more proactively within existing workflows, thus boosting patient adherence.
Blood Glucose Data Directly Embedded in EHR
Diabetes is the
Read More
